The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Shares in Berkshire Hathaway hit a record high closing price of $537.72 on the day Trump unveiled sweeping tariffs, which the president dubbed "Liberation Day". The stock fell sharply in the following ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...